Projects per year
Personal profile
Biography
Stephen Opat is the director of Clinical Haematology at Monash Health, a dynamic academic research organization that integrates the best evidence–base into routine patient care. It provides haematology care to a population of approximately 1.3 million, making it one of the largest services in Australia. Key leadership areas in clinical care and research include: Lymphoid cancer, chronic myeloid disorders, thromboembolic disease, haemoglobinopathy and transfusion medicine. It is an active member of a number of research organisations including the Monash Health Translation Precinct (MHTP), the Centre for Cancer Research (CCR) at the Hudson Institute of Medical Research, and the Australasian Leukaemia and Lymphoma Group. His particular interests include the diagnosis and management of lymphoma and chronic lymphocytic leukaemia, cancer genomics, disorders of iron metabolism, Gaucher disease and novel therapies. He is the principal investigator in over 30 clinical trials mainly in lymphoid cancer and founder of the Australasian Lymphoma and Related Diseases Registry. He has a strong interest in medical education, particularly in developing countries, and has lectured widely throughout the Asia-Pacific. He is extremely active in the Haematology Society of Australia and New Zealand where he currently serves as President.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Lymphoma
- Genomics
- Chronic Lymphocytic Leukaemia
- Cancer Immunology
- Cancer Cell Biology
Collaborations and top research areas from the last five years
-
A Phase 1/1b Open-Label Dose-Escalation Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies
1/08/24 → 31/07/29
Project: Research
-
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era
Baggio, D., Chung, E., Wellard, C., Waters, N., Cushion, T., Chong, G., Cochrane, T., Cull, G., Giri, P., Hamad, N., Johnston, A., Lee, D., Murali, A., Morgan, S., Mulligan, S., Talaulikar, D., Ratnasingam, S., Wood, E., Hawkes, E. & Opat, S., Jul 2024, In: Internal Medicine Journal. 54, 7, p. 1223-1227 5 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Chronic Lymphocytic Leukemia: Time to Care for the Survivors
Fedele, P. L. & Opat, S., 10 Jun 2024, In: Journal of Clinical Oncology. 42, 17, p. 2005-2011 7 p.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access5 Citations (Scopus) -
Large cell lymphoma through a liquid lens
Shortt, J. & Opat, S., Jul 2024, In: British Journal of Haematology. 205, 1, p. 15-16 2 p.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access -
Reply to Y. Song et al
Dimopoulos, M. A., Opat, S., Treon, S. P. & Tam, C. S., 1 Feb 2024, In: Journal of Clinical Oncology. 42, 4, p. 482-484 3 p.Research output: Contribution to journal › Letter › Other › peer-review
-
Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes
Mo, A., Wood, E., Shortt, J., Charlton, A., Evers, D., Hoeks, M., Pritchard, E., Daly, J., Hodgson, C., Opat, S., Bowen, D., Reynolds, J., Thi Phuong Thao, L., Stanworth, S. J. & McQuilten, Z., Feb 2024, In: Transfusion. 64, 2, p. 236-247 12 p.Research output: Contribution to journal › Article › Other › peer-review
Open Access